{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:14:52Z","timestamp":1794374092037,"version":"4.9.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05772-5","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T05:51:07Z","timestamp":1735969867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3906-480X","authenticated-orcid":false,"given":"Lakshmi","family":"Kattamuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5554-3342","authenticated-orcid":false,"given":"Bhavesh","family":"Mohan Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7238-1058","authenticated-orcid":false,"given":"Nikhil","family":"Vojjala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1599-9497","authenticated-orcid":false,"given":"Mansi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5720-0706","authenticated-orcid":false,"given":"Kunal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4065-5880","authenticated-orcid":false,"given":"Siddharth","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"issue":"4","key":"5772_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","volume":"278","author":"L Wang","year":"2015","unstructured":"Wang L, Wang FS, Gershwin ME (2015) Human autoimmune diseases: a comprehensive update. J Intern Med 278(4):369\u2013395","journal-title":"J Intern Med"},{"issue":"10416","key":"5772_CR2","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett G, Mackensen A, Mougiakakos D (2023) CAR T-cell therapy in autoimmune diseases. Lancet 402(10416):2034\u20132044","journal-title":"Lancet"},{"issue":"25","key":"5772_CR3","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572\u20132581","journal-title":"N Engl J Med"},{"issue":"1","key":"5772_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222\u2013233","journal-title":"Arthritis Rheum"},{"key":"5772_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/jcm10173773","volume":"10","author":"E Treppo","year":"2021","unstructured":"Treppo E, Binutti M, Agarinis R, De Vita S, Quartuccio L (2021) Rituximab induction and maintenance in ANCA-associated vasculitis: state of the art and future perspectives. J Clin Med 10:17","journal-title":"J Clin Med"},{"issue":"2","key":"5772_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314\u2013324","journal-title":"Arthritis Rheum"},{"issue":"7","key":"5772_CR7","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y et al (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 3(7):e489\u2013e497","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"5772_CR8","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1002\/art.27541","volume":"62","author":"B Terrier","year":"2010","unstructured":"Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B et al (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62(8):2458\u20132466","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5772_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47(2):115\u2013123","journal-title":"Semin Hematol"},{"key":"5772_CR10","doi-asserted-by":"publisher","first-page":"175628641876169","DOI":"10.1177\/1756286418761697","volume":"11","author":"TG Forsthuber","year":"2018","unstructured":"Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, St\u00fcve O (2018) B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord 11:1756286418761697","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"5772_CR11","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/art.22810","volume":"56","author":"JH Anolik","year":"2007","unstructured":"Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I (2007) Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56(9):3044\u20133056","journal-title":"Arthritis Rheum"},{"issue":"6382","key":"5772_CR12","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361\u20131365","journal-title":"Science"},{"key":"5772_CR13","doi-asserted-by":"crossref","unstructured":"Al Hadidi S, Heslop HE, Brenner MK, Suzuki M (2024) Bispecific antibodies and autologous chimeric antigen receptor T\u00a0cell therapies for treatment of hematological malignancies. Mol Ther","DOI":"10.1016\/j.ymthe.2024.05.039"},{"key":"5772_CR14","doi-asserted-by":"crossref","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science translational medicine. 2011;3(95):95ra73\u201395ra73.","DOI":"10.1126\/scitranslmed.3002842"},{"issue":"8","key":"5772_CR15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725\u2013733","journal-title":"N Engl J Med"},{"issue":"8","key":"5772_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann C, M\u00fcller F, Distler JHW, Gy\u00f6rfi AH, V\u00f6lkl S, Aigner M et al (2023) Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis 82(8):1117\u20131120","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"5772_CR17","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D et al (2023) CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329(24):2154\u20132162","journal-title":"JAMA"},{"issue":"6","key":"5772_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S et al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385(6):567\u2013569","journal-title":"N Engl J Med"},{"issue":"10379","key":"5772_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller F, Boeltz S, Knitza J, Aigner M, V\u00f6lkl S, Kharboutli S et al (2023) CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401(10379):815\u2013818","journal-title":"Lancet"},{"issue":"8","key":"5772_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S et al (2024) CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up. N Engl J Med 390(8):687\u2013700","journal-title":"N Engl J Med"},{"key":"5772_CR21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1126\/scitranslmed.aav1648","volume":"11","author":"R Kansal","year":"2019","unstructured":"Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M et al (2019) Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 11:482","journal-title":"Sci Transl Med"},{"key":"5772_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"11","key":"5772_CR23","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409\u20131417","journal-title":"Rheumatol Int"},{"issue":"2","key":"5772_CR24","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288\u2013291","journal-title":"J Rheumatol"},{"key":"5772_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8:1","journal-title":"Lupus Sci Med"},{"issue":"1","key":"5772_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae S-C et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15\u201329","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5772_CR27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM et al (2017) 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 76(5):792\u2013801","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"5772_CR28","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1007\/s10067-020-05126-z","volume":"39","author":"L Ross","year":"2020","unstructured":"Ross L, Stevens W, Wilson M, Huq M, Strickland G, Walker J et al (2020) Performance of the 2017 EUSTAR activity index in an scleroderma cohort. Clin Rheumatol 39(12):3701\u20133705","journal-title":"Clin Rheumatol"},{"issue":"12","key":"5772_CR29","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1002\/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U","volume":"44","author":"VD Steen","year":"2001","unstructured":"Steen VD, Medsger TA Jr (2001) Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 44(12):2828\u20132835","journal-title":"Arthritis Rheum"},{"issue":"10","key":"5772_CR30","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127\u20132133","journal-title":"JBI Evid Synth"},{"issue":"6","key":"5772_CR31","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","volume":"17","author":"W Zhang","year":"2021","unstructured":"Zhang W, Feng J, Cinquina A, Wang Q, Xu H, Zhang Q et al (2021) Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR. Stem Cell Rev Rep 17(6):2120\u20132123","journal-title":"Stem Cell Rev Rep"},{"issue":"4","key":"5772_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1056\/NEJMc2403743","volume":"391","author":"M Li","year":"2024","unstructured":"Li M, Zhang Y, Jiang N, Ning C, Wang Q, Xu D et al (2024) Anti\u2013CD19 CAR T cells in refractory immune thrombocytopenia of SLE. N Engl J Med 391(4):376\u2013378","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"5772_CR33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/annrheumdis-2023-eular.4161","volume":"82","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He S, Zhang W, Zhang H, Destefano V, Wada M et al (2023) POS1134\u2005novel approach to treat systemic lupus erythematosus, by targeting the \u201croot cause\u201d, B cells and plasma cells, using BCMA-CD19 compound car. Ann Rheum Dis 82(Suppl 1):895","journal-title":"Ann Rheum Dis"},{"key":"5772_CR34","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1182\/blood-2023-186669","volume":"142","author":"J Feng","year":"2023","unstructured":"Feng J, Hu Y, Chang AH, Huang H (2023) CD19\/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus: safety and preliminary efficacy data from a phase I clinical study. Blood 142:4835","journal-title":"Blood"},{"issue":"10","key":"5772_CR35","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M et al (2024) BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis 83(10):1304\u20131314","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"5772_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/annrheumdis-2024-eular.3334","volume":"83","author":"G Schett","year":"2024","unstructured":"Schett G, Bohr D, Mueller F, Hagen M, Bergmann C, Tur C et al (2024) POS0030\u2005safety and preliminary efficacy of CD19 CAR-T cell treatment in rheumatic disease- data from the first part of the phase I\/II castle basket study. Ann Rheum Dis 83(Suppl 1):327","journal-title":"Ann Rheum Dis"},{"key":"5772_CR37","first-page":"1","volume":"11","author":"P Amber","year":"2024","unstructured":"Amber P, Richard F, Francis K, Justin C, Ranjita S, Ruthee B et al (2024) P95 First two US patients with lupus nephritis (LN) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy: preliminary results from the KYSA-1 phase 1, multicenter study of KYV-101. Lupus Sci Med 11:1","journal-title":"Lupus Sci Med"},{"key":"5772_CR38","unstructured":"Auth J, M\u00fcller F, V\u00f6lkl S, Bayerl N, Distler JHW, Tur C, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol"},{"issue":"18","key":"5772_CR39","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L et al (2024) Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 187(18):4890\u2013904.e9","journal-title":"Cell"},{"key":"5772_CR40","doi-asserted-by":"crossref","unstructured":"Merkt W, Freitag M, Claus M, Kolb P, Falcone V, R\u00f6hrich M, et al. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis 2024; 83(4):543\u20136.","DOI":"10.1136\/ard-2023-225174"},{"issue":"11","key":"5772_CR41","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/ard-2024-226017","volume":"83","author":"A Haghikia","year":"2024","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, B\u00f6ttcher M, Pappa V, Motte J et al (2024) Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann Rheum Dis 83(11):1597\u20131598","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5772_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004727","volume":"10","author":"D Szabo","year":"2024","unstructured":"Szabo D, Balogh A, Gopcsa L, Giba-Kiss L, Lakatos G, Paksi M et al (2024) Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. RMD Open 10(4):e004727","journal-title":"RMD Open"},{"issue":"11","key":"5772_CR43","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","volume":"32","author":"J Volkov","year":"2024","unstructured":"Volkov J, Nunez D, Mozaffar T, Stadanlick J, Werner M, Vorndran Z et al (2024) Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial. Mol Ther 32(11):3821\u20133828","journal-title":"Mol Ther"},{"issue":"3","key":"5772_CR44","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1111\/bjh.16266","volume":"188","author":"JL Schmelz","year":"2020","unstructured":"Schmelz JL, Navsaria L, Goswamy R, Chuang HH, Miranda RN, Lee HJ (2020) Chimeric antigen receptor T-cell therapy\u2019s role in antiphospholipid syndrome: a case report. Br J Haematol 188(3):e5\u2013e8","journal-title":"Br J Haematol"},{"key":"5772_CR45","doi-asserted-by":"crossref","unstructured":"Friedberg E, Wohlfarth P, Schiefer AI, Skrabs C, Pickl WF, Worel N, et al. (2024) Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost","DOI":"10.1016\/j.jtha.2024.09.024"},{"key":"5772_CR46","doi-asserted-by":"publisher","first-page":"1298815","DOI":"10.3389\/fimmu.2023.1298815","volume":"14","author":"L Sheng","year":"2023","unstructured":"Sheng L, Zhang Y, Song Q, Jiang X, Cao W, Li L et al (2023) Concurrent remission of lymphoma and Sj\u00f6gren\u2019s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report. Front Immunol 14:1298815","journal-title":"Front Immunol"},{"issue":"12","key":"5772_CR47","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov\u00e1 D et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918\u20133930","journal-title":"Arthritis Rheum"},{"issue":"8","key":"5772_CR48","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y et al (2021) Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol 18(8):1896\u20131903","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"5772_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342","journal-title":"Lancet Oncol"},{"issue":"4","key":"5772_CR50","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole OO, Bouabdallah K, Mu\u00f1oz J, De Guibert S, Vose JM, Bartlett NL et al (2021) Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol 194(4):690\u2013700","journal-title":"Br J Haematol"},{"issue":"1","key":"5772_CR51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G et al (2022) Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23(1):91\u2013103","journal-title":"Lancet Oncol"},{"issue":"7","key":"5772_CR52","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO et al (2022) Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 386(7):640\u2013654","journal-title":"N Engl J Med"},{"issue":"14","key":"5772_CR53","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382(14):1331\u20131342","journal-title":"N Engl J Med"},{"issue":"3","key":"5772_CR54","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT et al (2023) Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol 41(3):555\u2013567","journal-title":"J Clin Oncol"},{"issue":"10299","key":"5772_CR55","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD et al (2021) KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398(10299):491\u2013502","journal-title":"Lancet"},{"issue":"1","key":"5772_CR56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jtct.2023.10.017","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C et al (2024) Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther 30(1):77","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"5772_CR57","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","volume":"57","author":"K Wudhikarn","year":"2022","unstructured":"Wudhikarn K, Perales M-A (2022) Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant 57(10):1477\u20131488","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"5772_CR58","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA et al (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377(26):2531\u20132544","journal-title":"N Engl J Med"},{"issue":"6","key":"5772_CR59","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/rheumatology\/kem001","volume":"46","author":"GG Illei","year":"2007","unstructured":"Illei GG, Yarboro CH, Kuroiwa T, Schlimgen R, Austin HA, Tisdale JF et al (2007) Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis. Rheumatology (Oxford) 46(6):952\u2013956","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5772_CR60","first-page":"352","volume":"26","author":"EM Adams","year":"1999","unstructured":"Adams EM, Pucino F, Yarboro C, Hicks JE, Thornton B, McGarvey C et al (1999) A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol 26(2):352\u2013360","journal-title":"J Rheumatol"},{"issue":"2","key":"5772_CR61","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ et al (2024) Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med 30(2):338\u2013341","journal-title":"Nat Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05772-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05772-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05772-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:17:55Z","timestamp":1737703075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05772-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["5772"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05772-5","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"18"}}